Last updated on November 2017

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to- Severe Acne Vulgaris (Study FX2017-22)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acne
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other:
  • Has facial acne vulgaris with:

    1. 20 to 50 inflammatory lesions (papules, pustules, and nodules)
    2. 25 to 100 non-inflammatory lesions (open and closed comedones)
    3. No more than 2 nodules on the face
    4. IGA score of moderate (3) to severe (4)

  • Willing to use only the supplied non-medicated cleanser (Cetaphil Gentle Skin Cleanser) and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study.

You may not be eligible for this study if the following are true:

  • Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations.
  • Sunburn on the face.